Rujukan Neurodegenerasi

  1. ↑ "What is Neurodegenerative Disease?". JPND Research. JPND Research. Dicapai pada February 7, 2015.
  2. 1 2 3 4 5 Rubinsztein DC (October 2006). "The roles of intracellular protein-degradation pathways in neurodegeneration". Nature. 443 (7113): 780–6. Bibcode:2006Natur.443..780R. doi:10.1038/nature05291. PMID 17051204.
  3. 1 2 3 4 5 6 "Cell death in the nervous system". Nature. 443 (7113): 796–802. October 2006. Bibcode:2006Natur.443..796B. doi:10.1038/nature05293. PMC 3970704. PMID 17051206.
  4. ↑ Wenk GL (2003). "Neuropathologic changes in Alzheimer's disease". J Clin Psychiatry. 64 Suppl 9: 7–10. PMID 12934968.
  5. ↑ "Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases". Neuromolecular Med. 4 (1–2): 21–36. 2003. doi:10.1385/NMM:4:1-2:21. PMID 14528050.
  6. ↑ "Synapse formation and function is modulated by the amyloid precursor protein". J. Neurosci. 26 (27): 7212–21. July 2006. doi:10.1523/JNEUROSCI.1450-06.2006. PMC 6673945. PMID 16822978.
  7. ↑ "Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory". Prog. Neurobiol. 70 (1): 1–32. May 2003. doi:10.1016/S0301-0082(03)00089-3. PMID 12927332.
  8. ↑ Hooper NM (April 2005). "Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein". Biochem. Soc. Trans. 33 (Pt 2): 335–8. doi:10.1042/BST0330335. PMID 15787600.
  9. ↑ "The importance of neuritic plaques and tangles to the development and evolution of AD". Neurology. 62 (11): 1984–9. June 2004. doi:10.1212/01.WNL.0000129697.01779.0A. PMID 15184601.
  10. ↑ "Amyloid fibrils from the viewpoint of protein folding". Cell. Mol. Life Sci. 61 (5): 511–24. March 2004. doi:10.1007/s00018-003-3264-8. PMID 15004691.
  11. ↑ "Epidemiology of Parkinson's disease". Rev Neurol (Paris). 172 (1): 14–26. 2016. doi:10.1016/j.neurol.2015.09.012. PMID 26718594.
  12. ↑ "Parkinson's Disease Mechanism Discovered," HHMI Research News June 22, 2006.
  13. 1 2 3 "Role of axonal transport in neurodegenerative diseases". Annual Review of Neuroscience. 31: 151–73. 2008. doi:10.1146/annurev.neuro.31.061307.090711. PMID 18558852.
  14. 1 2 "Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins". The Journal of Biological Chemistry. 285 (42): 32486–93. October 2010. doi:10.1074/jbc.M110.139576. PMC 2952250. PMID 20693280.
  15. ↑ "Glial cells as intrinsic components of non-cell autonomous neurodegenerative disease". Nat. Neurosci. 10 (11): 1355–60. November 2007. doi:10.1038/nn1988. PMC 3110080. PMID 17965655.
  16. ↑ Purves D, Augustine GA, Fitzpatrick D, Hall W, LaMantia AS, McNamara JO, Williams SM (2001). "Modulation of Movement by the Basal Ganglia - Circuits within the Basal Ganglia System". Dalam Dale Purves (penyunting). Neuroscience (ed. 2nd). Sunderland, MA: Sinauer Associates. ISBN 978-0-87893-742-4.
  17. ↑ "Excitotoxic neuronal death and the pathogenesis of Huntington's disease". Arch. Med. Res. 39 (3): 265–76. April 2008. doi:10.1016/j.arcmed.2007.11.011. PMID 18279698.
  18. ↑ Purves D, Augustine GA, Fitzpatrick D, Hall W, LaMantia AS, McNamara JO, Williams SM (2001). "Modulation of Movement by the Basal Ganglia - Box A. Huntington's Disease". Dalam Dale Purves (penyunting). Neuroscience (ed. 2nd). Sunderland, MA: Sinauer Associates. ISBN 978-0-87893-742-4.
  19. ↑ Crossman AR (May 2000). "Functional anatomy of movement disorders" (PDF). J. Anat. 196 (4): 519–25. doi:10.1046/j.1469-7580.2000.19640519.x. PMC 1468094. PMID 10923984.[pautan putus]
  20. ↑ "Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons". Nature Neuroscience. 10 (5): 615–22. May 2007. doi:10.1038/nn1876. PMC 3799799. PMID 17435755.
  21. ↑ "Non–cell autonomous effect of glia on motor neurons in an embryonic stem cell–based ALS model". Nature Neuroscience. 10 (5): 608–14. May 2007. doi:10.1038/nn1885. PMC 3139463. PMID 17435754.
  22. ↑ Julien JP (May 2007). "ALS: astrocytes move in as deadly neighbors". Nature Neuroscience. 10 (5): 535–7. doi:10.1038/nn0507-535. PMID 17453052.
  23. 1 2 "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases". Nature. 443 (7113): 787–95. October 2006. Bibcode:2006Natur.443..787L. doi:10.1038/nature05292. PMID 17051205.
  24. ↑ Bernstein C, Bernstein H. (1991) Aging, Sex, and DNA Repair. pages 121-139, Academic Press, San Diego. ISBN 0120928604 ISBN 978-0120928606
  25. ↑ "DNA Damage, DNA Repair, Aging, and Neurodegeneration". Cold Spring Harb Perspect Med. 5 (10): a025130. September 2015. doi:10.1101/cshperspect.a025130. PMC 4588127. PMID 26385091.
  26. ↑ Camandola, S., & Mattson, M. P. (2017). Brain metabolism in health, aging, and neurodegeneration. The EMBO Journal, 36(11), 1474-1492.
  27. 1 2 Thompson LM (April 2008). "Neurodegeneration: a question of balance". Nature. 452 (7188): 707–8. Bibcode:2008Natur.452..707T. doi:10.1038/452707a. PMID 18401401.
  28. 1 2 3 "Animal Models of Polyglutamine Diseases and Therapeutic Approaches". The Journal of Biological Chemistry. 284 (12): 7431–5. March 2009. doi:10.1074/jbc.R800065200. PMC 2658038. PMID 18957429.
  29. ↑ Orr HT (March 2009). "Unstable Nucleotide Repeat Minireview Series: A Molecular Biography of Unstable Repeat Disorders". The Journal of Biological Chemistry. 284 (12): 7405. doi:10.1074/jbc.R800067200. PMC 2658033. PMID 18957428.
  30. ↑ "Pathogenic Mechanisms of a Polyglutamine-mediated Neurodegenerative Disease, Spinocerebellar Ataxia Type 1". The Journal of Biological Chemistry. 284 (12): 7425–9. March 2009. doi:10.1074/jbc.R800041200. PMC 2658037. PMID 18957430.
  31. ↑ "Mitochondrial disorders in the nervous system". Annual Review of Neuroscience. 31: 91–123. 2008. doi:10.1146/annurev.neuro.30.051606.094302. PMID 18333761.
  32. ↑ "Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications". Oxid Med Cell Longev. 2017: 2525967. 2017. doi:10.1155/2017/2525967. PMC 5529664. PMID 28785371.
  33. 1 2 "Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target?". Mech. Ageing Dev. 161 (Pt A): 163–176. January 2017. doi:10.1016/j.mad.2016.09.005. PMC 5316312. PMID 27663141.
  34. ↑ "DNA damage and its links to neurodegeneration". Neuron. 83 (2): 266–282. July 2014. doi:10.1016/j.neuron.2014.06.034. PMC 5564444. PMID 25033177.
  35. ↑ "DNA repair deficiency in neurodegeneration". Prog. Neurobiol. 94 (2): 166–200. July 2011. doi:10.1016/j.pneurobio.2011.04.013. PMC 3123739. PMID 21550379.
  36. ↑ Coleman MP & Freeman MF 'Wallerian degeneration, WldS and Nmnat' Annual Review of Neuroscience 2010, 33: 245-67
  37. ↑ "Bacterial Programmed Cell Death and Multicellular Behavior in Bacteria". PLOS Genetics. 2 (10): e135. October 2006. doi:10.1371/journal.pgen.0020135. PMC 1626106. PMID 17069462.
  38. 1 2 Vila, Miquel; Przedbroski, Serge (May 2003). "Targeting Programmed Cell Death in Neurodegenrative Diseases". Nature Reviews Neuroscience. 4 (5): 365–375. doi:10.1038/nrn1100. PMID 12728264.
  39. ↑ "Pharmacological manipulation of cell death: clinical applications in sight?". The Journal of Clinical Investigation. 115 (10): 2610–7. October 2005. doi:10.1172/JCI26321. PMC 1236695. PMID 16200193.
  40. 1 2 3 4 5 6 7 8 9 "Critical role of transglutaminase and other stress proteins during neurodegenerative processes". Amino Acids. 38 (2): 653–8. 2010. doi:10.1007/s00726-009-0428-3. PMID 19960212.
  41. ↑ Dimebon Disappoints in Phase 3 Trial
  42. ↑ Sweetlove M: Phase III CONCERT Trial of Latrepirdine. Negative results. Pharm Med 2012;26(2):113-115
  43. ↑ "Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25–35 model of Alzheimer's disease". Alzheimer's & Dementia. 4 (5): 332–44. September 2008. doi:10.1016/j.jalz.2007.10.019. PMID 18790460.
  44. ↑ "Active and Passive Immunotherapy for Neurodegenerative Disorders". Annual Review of Neuroscience. 31: 175–93. 2008. doi:10.1146/annurev.neuro.31.060407.125529. PMC 2561172. PMID 18352830.
  45. ↑ Pastorino, L; Ikin, A. F; Lamprianou, S; Vacaresse, N; Revelli, J. P; Platt, K; Paganetti, P; Mathews, P. M; Harroch, S (2004-04-01). "BACE (β-secretase) modulates the processing of APLP2 in vivo". Molecular and Cellular Neuroscience (dalam bahasa Inggeris). 25 (4): 642–649. doi:10.1016/j.mcn.2003.12.013. ISSN 1044-7431.
  46. ↑ Esch, F.; Keim, P.; Beattie, E.; Blacher, R.; Culwell, A.; Oltersdorf, T; McClure, D; Ward, P. (1990-06-01). "Cleavage of amyloid beta peptide during constitutive processing of its precursor". Science (dalam bahasa Inggeris). 248 (4959): 1122–1124. doi:10.1126/science.2111583. ISSN 0036-8075.
  47. ↑ Schenk, D.; Basi, G. S.; Pangalos, M. N. (2012-09-01). "Treatment Strategies Targeting Amyloid -Protein". Cold Spring Harbor Perspectives in Medicine (dalam bahasa Inggeris). 2 (9): a006387–a006387. doi:10.1101/cshperspect.a006387. ISSN 2157-1422.
Klasifikasi